170 related articles for article (PubMed ID: 20230864)
21. Impact of ester promoieties on transdermal delivery of ketorolac.
Liu KS; Hsieh PW; Aljuffali IA; Lin YK; Chang SH; Wang JJ; Fang JY
J Pharm Sci; 2014 Mar; 103(3):974-86. PubMed ID: 24481782
[TBL] [Abstract][Full Text] [Related]
22. Ionized prodrugs of dehydroepiandrosterone for transdermal iontophoretic delivery.
Laneri S; Sacchi A; di Frassello EA; Luraschi E; Colombo P; Santi P
Pharm Res; 1999 Dec; 16(12):1818-24. PubMed ID: 10644068
[TBL] [Abstract][Full Text] [Related]
23. Topical iontophoretic delivery of ionizable, biolabile aciclovir prodrugs: A rational approach to improve cutaneous bioavailability.
Chen Y; Alberti I; Kalia YN
Eur J Pharm Biopharm; 2016 Feb; 99():103-13. PubMed ID: 26686649
[TBL] [Abstract][Full Text] [Related]
24. Transdermal delivery of atenolol: effect of prodrugs and iontophoresis.
Anroop B; Ghosh B; Parcha V; Khanam J
Curr Drug Deliv; 2009 Jul; 6(3):280-90. PubMed ID: 19604142
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and evaluation of Ketorolac ester prodrugs for transdermal delivery.
Doh HJ; Cho WJ; Yong CS; Choi HG; Kim JS; Lee CH; Kim DD
J Pharm Sci; 2003 May; 92(5):1008-17. PubMed ID: 12712420
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo iontophoretic transdermal delivery of an anti-parkinsonian agent.
Vemulapalli V; Yang Y; Siddoju S; Conjeevaram R; Teunissen H; Myers T; Banga AK
Int J Pharm; 2011 Nov; 420(1):20-5. PubMed ID: 21856395
[TBL] [Abstract][Full Text] [Related]
27. Solubility and solution stability studies of different amino acid prodrugs of bromhexine.
Aggarwal AK; Gupta M
Drug Dev Ind Pharm; 2012 Nov; 38(11):1319-27. PubMed ID: 22283553
[TBL] [Abstract][Full Text] [Related]
28. Controlled iontophoretic delivery of pramipexole: electrotransport kinetics in vitro and in vivo.
Kalaria DR; Patel P; Merino V; Patravale VB; Kalia YN
Eur J Pharm Biopharm; 2014 Sep; 88(1):56-63. PubMed ID: 24525072
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of transdermal apomorphine delivery with a diester prodrug strategy.
Liu KS; Sung KC; Al-Suwayeh SA; Ku MC; Chu CC; Wang JJ; Fang JY
Eur J Pharm Biopharm; 2011 Aug; 78(3):422-31. PubMed ID: 21315820
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of esmolol prodrugs for transdermal delivery.
Bijaya G; Kaushal D; Sonal D; Pallavi K
Drug Deliv; 2010; 17(7):532-40. PubMed ID: 20553111
[TBL] [Abstract][Full Text] [Related]
31. Transdermal iontophoresis of dexamethasone sodium phosphate in vitro and in vivo: effect of experimental parameters and skin type on drug stability and transport kinetics.
Cázares-Delgadillo J; Balaguer-Fernández C; Calatayud-Pascual A; Ganem-Rondero A; Quintanar-Guerrero D; López-Castellano AC; Merino V; Kalia YN
Eur J Pharm Biopharm; 2010 Jun; 75(2):173-8. PubMed ID: 20332024
[TBL] [Abstract][Full Text] [Related]
32. Delivery of nalbuphine and its prodrugs across skin by passive diffusion and iontophoresis.
Sung KC; Fang JY; Hu OY
J Control Release; 2000 Jun; 67(1):1-8. PubMed ID: 10773323
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of piperazinylalkyl ester prodrugs of ketorolac and their in vitro evaluation for transdermal delivery.
Qandil A; Al-Nabulsi S; Al-Taani B; Tashtoush B
Drug Dev Ind Pharm; 2008 Oct; 34(10):1054-63. PubMed ID: 18608464
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, stereoselective enzymatic hydrolysis, and skin permeation of diastereomeric propranolol ester prodrugs.
Udata C; Tirucherai G; Mitra AK
J Pharm Sci; 1999 May; 88(5):544-50. PubMed ID: 10229647
[TBL] [Abstract][Full Text] [Related]
35. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of salicylic acid fatty ester prodrugs for UV protection.
Im JS; Balakrishnan P; Oh DH; Kim JS; Jeon EM; Kim DD; Yong CS; Choi HG
Drug Dev Ind Pharm; 2011 Jul; 37(7):841-8. PubMed ID: 21244220
[TBL] [Abstract][Full Text] [Related]
37. An improved design of water-soluble propofol prodrugs characterized by rapid onset of action.
Lang BC; Yang J; Wang Y; Luo Y; Kang Y; Liu J; Zhang WS
Anesth Analg; 2014 Apr; 118(4):745-54. PubMed ID: 24651228
[TBL] [Abstract][Full Text] [Related]
38. Dipeptidyl peptidase IV (DPPIV/CD26)-based prodrugs of hydroxy-containing drugs.
Diez-Torrubia A; Cabrera S; Lambeir AM; Balzarini J; Camarasa MJ; Velázquez S
ChemMedChem; 2012 Apr; 7(4):618-28. PubMed ID: 22307932
[TBL] [Abstract][Full Text] [Related]
39. New prodrugs of the antiprotozoal drug pentamidine.
Kotthaus J; Kotthaus J; Schade D; Schwering U; Hungeling H; Müller-Fielitz H; Raasch W; Clement B
ChemMedChem; 2011 Dec; 6(12):2233-42. PubMed ID: 21984033
[TBL] [Abstract][Full Text] [Related]
40. An in-vitro and in-vivo correlative approach to the evaluation of ester prodrugs to improve oral delivery of propranolol.
Shameem M; Imai T; Otagiri M
J Pharm Pharmacol; 1993 Apr; 45(4):246-52. PubMed ID: 8098362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
